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Abstract 
Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous 
cellular processes. Deregulation of FGFR signalling is frequently observed in many 
cancers, making activated FGF receptors a highly promising potential therapeutic 
target supported by multiple pre-clinical studies. However, early phase clinical trials 
have produced mixed results with FGFR-targeted cancer therapies, revealing 
substantial complexity to targeting aberrant FGFR signalling. In this Review, we 
discuss the increasing understanding of the differences between diverse 
mechanisms of oncogenic activation of FGFR, and the factors that determine 
response and resistance to FGFR targeting. 
Introduction  
Fibroblast growth factor receptors (FGFRs) form a family of four highly conserved 
trans-membrane receptor tyrosine kinases (FGFR1-4), and one receptor that has the 
ability to bind fibroblast growth factor (FGF) ligands but lacks an intracellular kinase 
domain (FGFR5, also known as FGFRL1)1. Receptor activation by FGFs initiates a 
cascade of intracellular events that activate major survival and proliferative signalling 
pathways2. FGFs mediate crucial physiological mechanisms, such as tissue and 
metabolism homeostasis, endocrine functions and wound repair2.  
 
Deregulation of the FGF signalling axis has been implicated in oncogenesis, tumour 
progression and resistance to anti-cancer therapy across many tumour types3. 
Although multiple studies have proposed aberrant FGFR signalling pathway as a 
potential therapeutic target in various tumour types, the efficacy of anti-FGFR 
therapy in the clinic has been variable4. Responses to therapy have been reported in 
early phase clinical trials for patients who harbour FGFR2 amplification in gastric 
cancer5, and FGFR2 and FGFR3 translocations in cholangiocarcinoma and urothelial 
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cancers6 respectively, although results from later phase studies are awaited. 
Disappointingly, modest levels of clinical activity have been reported for patients with 
other aberrations such as FGFR1 amplification7 or FGFR2 mutation in advanced-
stage endometrial cancer8.  
 
Nevertheless, as more data emerge as a result of clinical trials and functional 
studies, we begin to discern which FGFR aberrations are oncogenic drivers and 
would benefit from monotherapy. Likewise, certain passenger FGFR anomalies are 
being identified as potential targets for combination therapy in select patient 
populations, particularly with respect to FGFR-mediated drug resistance. In this 
Review we address the diverse mechanisms of oncogenic FGFR signalling, 
focussing on success and limitations of the use of FGFR inhibitors in the clinic, and 
discuss the recent scientific findings that provide insight into the variable therapeutic 
effects of anti-FGFR therapy. 
[H1] Oncogenic FGFR signalling  
 
Enhanced FGFR signalling in oncogenesis is mediated by genetic alterations 
(receptor amplification, mutations and chromosomal translocations); autocrine and 
paracrine signalling, angiogenesis and epithelial-mesenchymal transition (EMT) 
(Figure 1).  
 
[H3] FGFR amplification 
 
Amplification of FGFR1 (8q12 locus) is found in approximately 17% of squamous 
non-small cell lung carcinoma (NSCLC)9,10 and ~6% of small cell lung carcinoma11, 
and is an independent adverse prognostic marker in early stage NSCLC12. FGFR1 
amplification is also prevalent in breast cancer and was reported in nearly 15% of 
hormone-receptor positive and in around 5% of the more aggressive, triple-negative 
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breast cancers13-15. Response to FGFR inhibition has been observed in vitro in 
FGFR1-amplified lung cancer models, of both squamous and non-squamous types, 
although response to FGFR inhibition in xenografts has been variable10,16. In vitro 
inhibition of FGFR1 through small interfering RNA (siRNA) or a selective FGFR 
inhibitor PD173074 modestly reduced the growth of breast cancer cell lines that 
overexpressed FGFR1 or in which FGFR1 was amplified17,18. However, FGFR 
inhibition can reverse resistance to endocrine therapy promoted by FGFR 
signalling31. Large-scale kinase profiling of 117 cell lines of several cancer types 
revealed increased sensitivity of FGFR1- and FGFR2-amplified osteosarcoma cell 
lines to several FGFR inhibitors19, which was confirmed in a study of 500 cell lines, in 
response to FGFR inhibitor NVP-BGJ39820. 
 
Amplification of FGFR2 is less frequent than amplification of FGFR1 across cancer 
types, and has only been described in 5-10% of gastric cancer, particularly of the 
aggressive diffuse subtype 21, and in 2% of breast cancer overall, with approximately 
4% of triple negative breast cancer harbouring FGFR2 amplification22. Amplified 
FGFR2 in some cancers, such as diffuse gastric cancer, is accompanied by deletion 
of the C-terminal exon, which results in preferential expression of a truncated form of 
the receptor potentially promoting oncogenesis through impaired internalisation and 
subsequent degradation of the active receptor23. Gastric24, rectal25 and breast 
cancer19 cell lines with high levels of amplification of FGFR2 are highly sensitive to 
selective FGFR inhibitor in vitro and in vivo, which suggests that FGFR2 amplification 
in these cancers could signify addiction to the FGFR pathway for growth.  
 
Differences in apparent addiction to FGFR1 and FGFR2 amplification are in part 
explained by the amplicon: the FGFR2 amplicon is frequently narrow and centred on 
FGFR2 with few other genes co-amplified, whereas the FGFR1 amplicon is usually 
broad, with co-amplification of several genes potentially contributing to 
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carcinogenesis. The amplification is frequently broader in oestrogen receptor (ER)-
positive breast cancer than in NSCLC, with strong evidence pointing at ZNF703 
oncogene as a further driver in the FGFR1 amplicon26,27, which may also predict 
resistance to tamoxifen28. Amplification of FGFR3 and FGFR4 is not frequently 
reported, and oncogenic activation of these receptors is often linked to a mutation, or 
ligand amplification. For example, FGFR3 protein overexpression is recurrent in 
bladder cancer but it is not linked to FGFR3 gene amplification29,30. 
 
[H3] Activating mutations 
 
In contrast to activating mutations in EGFR, mutations in FGFRs are frequently 
observed outside the kinase domain (Figure 2). Somatic activating mutations of 
FGFR1 are rarely observed in cancer, and are more common in FGFR2 and FGFR3.  
 
FGFR2 mutations are found in 10-12% of endometrial carcinomas31,32, nearly 4% of 
NSCLC and gastric cancer33, as well as in around 2% of urothelial cancer34. 
Mutations in the extracellular IgII and IgIII loops (Figure 2), as well as in their linker 
domain, may provide gain of function either through increasing receptor-ligand 
binding affinity and interaction35,36 (for example the S252W mutation in FGFR2, with 
an identical mechanism described for the P252 residue in FGFR1 and P250 in 
FGFR335) or through generation of aberrant disulphide bridges that result in 
constitutive receptor dimerization (S373C and Y376C in the FGFR2-IIIc isoform and 
analogous mutations in FGFR3-IIIc, G370C and Y373C37). Similarly, FGFR2 
insertion mutation A266_S267ins and deletion 290_291WI>C, where amino acid 
residues WI are replaced by a Cysteine (C), have recently been described to have 
oncogenic potential via increased dimer formation in a ligand-independent manner38. 
Mutations in FGFR3 are very frequent in non-muscle invasive urothelial cell 
carcinomas (75%), also occurring in around 15% of high-grade invasive urothelial 
 6 
cancer32,39 and around 5% of cervical cancer39,40. The most common mutations in 
FGFR3 also occur in the extracellular (R248, S249) and transmembrane (G370, 
Y373) domains of the receptor, resulting in increased receptor dimerization and 
ligand-independent signalling, analogous to FGFR2 mutations in those regions41. 
Although it is likely that enhanced dimerization directly leads to upregulation of FGFR 
kinase activity, this has not been established yet and additional factors might be 
required. 
 
Mutations in the kinase domain of FGFR1 and FGFR2 (most frequently N546K and 
N549H/K, respectively) constitutively activate the receptors and transform cell 
lines42,43, although these mutations are rare, with the FGFR2 N549 mutations found 
in around 1.4% endometrial and <1% invasive breast cancers34. FGFR4 kinase 
mutations K535 and E550 have been recorded in rhabdomyosarcoma44 and 
knockdown of FGFR4 with inducible short hairpin RNA (shRNA) in a human 
rhabdomyosarcoma cell line reduced tumour growth in vivo44.  
 
In addition to the somatic activating mutations in the FGFRs, germline single 
nucleotide polymorphisms (SNPs) have been reported to associate with cancer 
incidence. A non-coding SNP in the second intron of FGFR2 (rs2981582), which 
contains putative transcription factor binding sites, has been linked to predisposition 
to breast cancer in postmenopausal women45-47. A SNP in FGFR4 (rs351855), which 
results in G388R substitution, is linked to poor survival in several cancer types, such 
as breast, colorectal and lung, among others48, and has been shown to increase 
breast cancer cell motility in vitro49. This genetic association of the rs351855 SNP 
with cancer aggressiveness can at least in part be explained by increased 
association of FGFR4 harbouring the SNP with signal transducer and activator of 
transcription 3 (STAT3)50. The G388R substitution results in a conformational change 
of the receptor, thereby exposing a membrane-proximal STAT3 binding site, with 
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expression of the FGFR4_G388R variant significantly enhanced STAT3 signalling in 
knock-in mice and transgenic mouse models for breast and lung cancers50.  
 
[H3] Oncogenic fusions 
More recently, activating gene fusions in the FGFRs have been discovered in a 
number of cancers, typically at low incidence51,52 (Table 1). The majority of FGFR 
fusion partners contain dimerization domains, which induce ligand-independent 
receptor dimerization and oncogenic effects. FGFR3 fusions are relatively common 
in glioblastoma and bladder cancer, with rare reports in lung cancer52. Many FGFR3 
gene fusions are with transforming acidic coiled-coil containing protein 3 (TACC3), in 
which the coiled coil domain is involved in protein oligomerisation and protein-protein 
interactions53,54. In the FGFR3-TACC3 fusion protein, the final exon at the C-terminus 
of FGFR3 is replaced with TACC3, which results in oncogenic constitutive kinase 
activity, localisation of the fused protein to spindle poles and subsequent 
chromosomal segregation defects and aneuploidy51. The fused protein can activate 
MAPK/ERK and JAK/STAT signalling pathways, but not PKC, due to the loss of 
phospholipase C (PLCγ) binding site51,55. 
 
TACC3 is frequently FGFR3 3’ fusion partner whereas FGFR2 has several reported 
fusion partners. FGFR2 fusions are found in roughly 15% of intrahepatic 
cholangiocarcinoma56,57, and rarely in lung, thyroid and prostate cancers52. Many 
fusion proteins contain protein-binding domains (citron Rho-interacting kinase (CIT), 
coiled-coil domain-containing protein 6 (CCDC6), cell cycle and apoptosis regulator 
protein 2 (CCAR2, also known as KIAA1967), oral-facial-digital syndrome 1 protein 
(OFD1), BicC family RNA-binding protein 1 (BICC1)) fused to the cytoplasmic tail of 
FGFR2, deleting the C-terminal exon of FGFR252, similar to the deletion of this exon 
in some cancers with amplified FGFR2. The fusion partners likely mediate increased 
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fusion-receptor dimerization and ligand-independent signalling52. Interestingly, N-
terminal fusions of other proteins with FGFRs have also been reported. A fusion of 
the prohibitin -containing protein ER lipid raft associated 2 (ERLIN2) with FGFR1 has 
been described in breast cancer, and SLC45A3-FGFR2 gene fusion was identified in 
a patient with prostate cancer52. Although the most probable consequences of the 
described N-terminal fusions are increased receptor dimerization and increased 
kinase activation, the SLC45A3-FGFR2 gene fusion represents a unique pathogenic 
mechanism, in which the entire open reading frame of FGFR2 falls under the 
promoter of an androgen-regulated SLC45A3, resulting in overexpression of 
FGFR252. 
 
Overexpression of FGFR2-BICC1, FGFR3-brain-specific angiogenesis inhibitor 1-
associated protein 2-like protein 1 (BAIAP2L1), and FGFR3-TACC3 in 293T cells 
enhanced cancer cell proliferation in vitro, as well as increased susceptibility to 
FGFR inhibitors in vitro and in vivo52. Furthermore, stable expression of FGFR3-
BAIAP2L1, FGFR3-TACC3, and FGFR2-CCDC6 fusion proteins in a benign 
telomerase reverse transcriptase (hTERT) – human mammary epithelial (HME) 
mammary gland cell line promoted cell proliferation via increased MAPK/ERK and 
JAK/STAT pathway activation, highlighting a role for FGFRs in oncogenic 
transformation52. As more FGFR fusions emerge, their individual oncogenic potential 
will need to be investigated, particularly in the case of out-of-frame fusions.  
 
[H3] FGF ligand signalling, EMT and angiogenesis 
 
Deregulation of FGF expression and secretion in cancer or stromal cells may also 
contribute to or drive carcinogenesis. Most evidence for abnormal autocrine and 
paracrine FGF loops comes from xenograft and cell line models, particularly in 
prostate cancer. Multiple FGFs have been implicated in development and 
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progression of prostate cancer, including FGF1, FGF2, FGF6, FGF858-63 and more 
recently, endocrine FGF1962,63 and FGF2364,65 (Box 1). Amplification of the 11q13 
locus, including cyclin D1 (CCND1) and FGF3, FGF4 and FGF19, is frequent in 
many cancers. Although amplified FGFs are not expressed in many 11q13-amplified 
cancers66-68, in the 15% of hepatocellular carcinomas (HCC) with amplification of the 
11q13 locus, FGF19 is expressed and contributes to cancer pathogenesis69. 
Furthermore, transgenic mice with overexpression of FGF19 at an ectopic site 
(skeletal muscle) developed HCC by 10 months of age70, confirming the endocrine-
like oncogenic effects of FGF19 on hepatocytes. Pre-clinical studies showed that 
FGF19 stimulates tumour progression via activation of STAT371, and RNAi-mediated 
knockdown69 and neutralising antibodies against FGF1971,72 had a profound anti-
proliferative effect in HCC in vitro and in vivo models.  
FGF2, FGF8 and FGF9 are capable of facilitating EMT in cancer by inducing 
mesenchymal characteristics in of epithelial cells73-77, similar to their established roles 
during embryogenesis. High levels of FGF2 are expressed and secreted in triple-
negative breast cancer cell lines78, specifically of mesenchymal phenotype79. In 
patients, increased FGF2 levels in plasma are observed in many cancers, such as 
leukaemia, lung and breast cancers, particularly in metastatic disease80,81, likely 
reflecting increased release of FGF2 bound to heparan sulfate proteoglycans in the 
extracellular matrix by invading cancer cells, although this FGF2 release is of 
uncertain pathogenic relevance.  
 
Switching from an FGFR-IIIb isoform (with higher affinity for FGF1, FGF3, FGF7 and 
FGF10), which is enriched in epithelia, to a ‘mesenchymal’ IIIc isoform (with higher 
affinity for FGF1, FGF2, and FGF9)74,82,83 may facilitate EMT with enhanced FGF 
signalling via increased affinity for oncogenic FGFs secreted by the tumour or the 
surrounding stroma. The switch from FGFR2-IIIb to FGFR2-IIIc is associated with 
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increased invasiveness of bladder and prostate84, pancreatic85 and colon cancer cell 
lines 86.  
 
FGF2 has a key role in wound healing 87,88 and angiogenesis by promoting 
proliferation and migration of endothelial cells 89,90 in murine models, particularly in 
combination with vascular endothelial growth factor (VEGF)91,92..Increased FGF2 
levels were reported in patients who were resistant to anti-angiogenic agents93, 
indicating a possible role for FGFs in mediating resistance to anti-VEGF therapy (Box 
2). Indeed, dual inhibition of FGF and VEGF inhibited tumour growth and 
angiogenesis in mouse pancreatic neuroendocrine tumours that were resistant to 
VEGF inhibition94.  
 
[H3] Signal transducers 
Differential expression of key signal transducing proteins may shape the signal 
transduction pathways activated by FGFR signalling. FRS2 amplification and protein 
overexpression — which may promote MAPK/ERK signalling — were reported in 
undifferentiated high-grade pleomorphic sarcoma and ovarian cancer, and FRS2 
silencing reduced cell proliferation of liposarcoma and ovarian cancer cell lines95,96. 
Growth factor receptor-bound protein 2 (GRB2) and PLCγ compete for a mutual 
binding site on FGFR2, and reduced GRB2 levels translate into PLCγ-mediated 
cancer cell migration and invasion97. A combination of increased PLCγ and low 
GRB2 expression levels correlate with poor clinical prognosis in ovarian98 and lung99 
cancers. 
[H1] Targeting FGFR in the clinic 
 
The contribution of aberrant FGFR signalling to tumourigenesis has led to the 
development of a plethora of therapies targeting the FGFR pathway, many of which 
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were promising in pre-clinical studies of various tumour types harbouring FGFR 
aberrations. Although there are no FGFR-targeted therapies approved for the 
treatment of cancer at present, the results of a large number of early phase 
therapeutic trials have revealed important information on targeting FGFR in the clinic, 
with therapies including small molecule tyrosine kinase inhibitors (TKIs) that target 
the ATP-binding cleft of the kinase domains of several growth factor receptors (multi-
targeting TKIs), TKIs that selectively target the kinase domain of FGFRs (selective 
TKIs), monoclonal antibodies anti-FGFR and FGF ligand traps (Table 2).  
 
[H3] Multi-targeting TKIs 
 
The kinase domains of FGFR, VEGFR and platelet-derived growth factor receptor 
(PDGFR) families are phylogenetically related, and several non-selective TKIs 
originally developed to inhibit the VEGFRs also inhibit FGFR. Dovitinib (TKI258) is a 
non-selective TKI that targets VEGFR1-3, FGFR1-3 and PDGFRb at nanomolar 
concentrations7. Dovitinib demonstrated prominent anti-tumour activity in a phase I 
study in patients with renal cell carcinoma (RCC) 100, although reduced efficacy was 
observed in a phase II study in metastatic RCC patients101. A subsequent 
randomised phase III study of 570 patients for third line treatment for RCC 
demonstrated no difference in efficacy outcomes between dovitinib and sorafenib, 
another multi-targeting VEGFR inhibitor that does not appreciably inhibit FGFRs 101. 
Baseline levels of FGF2 did not predict for relative benefit, and were also not 
different between sorafenib and dovitinib when measured during treatment. These 
data questioned whether all efficacy of dovitinib in patients was through inhibition of 
VEGFR. In a separate phase II trial, treatment with dovitinib induced relatively 
infrequent partial responses in patients with FGFR1 or 11q13-amplified ER+ breast 
cancer, compared with no response in patients who harboured no amplifications 7, 
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potentially suggesting an oncogenic role for FGFRs in patients in whom FGFR1 or 
11q13 was amplified. 
 
Lucitanib (E3810) is another multi-TKI that targets FGFR1-2 and VEGFR1-3 among 
other tyrosine kinase receptors. A phase I/IIa study assessing lucitanib in solid 
tumours demonstrated clinical benefit in patients harbouring FGFR aberrations, with 
6 out of 12 patients achieving RECIST partial response 102. Additional non-selective 
TKI with anti-FGFR activity include nintedanib (BIBF1120) and ponatinib (AP24534), 
which so far demonstrated modest anti-tumour activities in advanced solid tumours103 
and leukaemia104.  
 
There is general uncertainty over whether these multi-targeting TKIs sufficiently 
inhibit FGFRs in the clinic. Dosing is limited by hypertension through VEGFR 
inhibition, and by non-specific toxicity102, with adverse effects specific to the selective 
FGFR inhibitors frequently not observed. Stratification of patients on the basis of their 
FGFR expression/mutation profile identified partial responses in breast cancers with 
FGFR1 (8q12) and/or 11q13 amplifications7. However it remains uncertain how much 
of the activity of these TKIs is through multi-targeted inhibition of VEGFR and other 
non-FGFR kinases. 
[H3] Selective inhibitors  
 
In order to facilitate on-target FGFR inhibition in patients who harbour FGFR 
abnormalities, and also reduce toxic effects associated with multi-TKIs, selective 
inhibitors of the FGFRs have been developed (Table 2). The kinase domains of 
FGFR1-3 show high structural similarity105, and most selective inhibitors inhibit all 
three FGFRs to varying degrees. The FGFR4 kinase domain is structurally distinct 
and is therefore not appreciably inhibited by most inhibitors106.  
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A retrospective analysis of the early selective inhibitor trials has revealed substantial 
variability in response rates between genetic aberrations. FGFR1-amplified cancers 
responded infrequently to selective FGFR inhibition. In a phase I study of AZD4547, 
an FGFR1-3 catalytic inhibitor, only one patient with FGFR1-amplified squamous 
NSCLC had a confirmed RECIST partial response (32% reduction in target lesions), 
from a total of 20 patients enrolled in the study107. In a phase I study of 132 patients 
with FGFR1-3 genetic aberrations, NVP-BGJ398 — a further FGFR1-3 selective 
inhibitor — demonstrated partial responses in four patients with FGFR1-amplified 
NSCLC, and stable disease in 14 patients108. Regarding breast cancer, in a phase II 
multicentre proof-of-concept study evaluating AZD4547, one out of eight patients 
with FGFR1-amplified breast cancer responded5 to the inhibitor. Similarly, only one 
patient with FGFR1-amplified breast cancer had a tumour regression when treated 
with NVP-BGJ398 in the phase I study108.  
 
The response rate in FGFR3-aberrant urothelial cancer is also uncertain. Two out of 
twenty patients with FGFR3-mutated bladder cancer achieved stable disease in 
response to AZD4547 in a phase I study107, although partial responses were also 
reported in FGFR3-mutated bladder cancer in a phase I trial of NVP-BGJ398108. 
Additional clinical data in patients harbouring FGFR mutations are required to reliably 
assess the potential of distinct individual FGFR mutations to predict response to 
targeted agents.  
 
By contrast, there have been high rates of response reported for FGFR2 
amplification. In a phase II trial evaluating AZD4547, three out of nine patients with 
FGFR2-amplified gastric cancer had a response to AZD4547 that lasted for 27–45 
weeks5. However, a separate phase II study showed no statistically-significant 
advantage of AZD4547 versus paclitaxel in patients with FGFR2-amplified advanced-
stage gastric cancer (41 patients assigned to the AZD4547 arm versus 30 patients in 
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paclitaxel arm)109, with evidence that response was limited by intra-tumoural 
heterogeneity, as discussed later in the Review.  
 
Tumours with FGFR fusions seem to have a high response rate to FGFR inhibition. 
Tumour shrinkage was observed in one cholangiocarcinoma and one HCC patient 
with FGFR2-BICC1 gene fusions in response to NVP-BGJ398 in a phase I study108. 
Consequently, this drug is now being investigated in phase II studies in advanced-
stage cholangiocarcinoma110, advanced-stage gastrointestinal stromal tumours 
(GIST)111 and other solid and haematologic malignancies112. Patients with urothelial 
tumours harbouring either FGFR2 truncation or FGFR3-TACC3 fusion also 
demonstrated clinical responses in a phase I dose-escalation study of JNJ-
427564936, which is now being assessed in a phase II study in unresectable 
urothelial cancers with FGFR genomic aberrations113. Two more inhibitors, 
LY2874455114 and TAS120112, are currently in phase I trials.  
 
Collectively, early trials of selective TKIs proved highly successful in targeting FGFR 
fusions and selected patients with FGFR2 amplification, although only marginal 
success was seen when targeting other FGFR aberrations.  
 
[H3] Monoclonal antibodies targeting FGF and FGFR  
 
Although several monoclonal antibodies (mAbs) against FGFRs have been 
developed, limited clinical data are currently available. MGFR1877S is an anti-
FGFR3 mAb that was evaluated in a phase I dose-escalation trial in patients with 
advanced-stage solid tumours115. Stable disease was reported to be the best 
response in patients with urothelial cell carcinoma (5 out of 10 patients), with 
thrombocytopenia, fatigue and nausea reported as predominant adverse effects116. 
Following promising in vitro findings, pre-clinical evaluation of an isoform-specific 
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mAb against FGFR1-IIIc, named IMC-A1, was shown to induce severe anorexia in 
animal models117, and thus was never translated into the clinic. The FGFR2-IIIb 
blocking mAb FPA144 inhibited growth of FGFR2-amplified gastric cancer xenografts 
by 72% to 100%118 and recently entered a phase I trial119. Data from 13 patients 
enrolled to date in this trial showed no dose-limiting toxic effects associated with 
FPA144 administration, with upper respiratory infection, alopecia and fatigue 
reported as adverse events in more than one patient120.  
 
FP-1039 is a FGF ligand trap; a soluble fusion protein that contains the extracellular 
domain of FGFR1-IIIc splice isoform and demonstrated anti-angiogenic and anti-
proliferative properties in multiple cancer cell line models via selective sequestration 
of non-hormonal FGFs121. Recently, a first in-human phase I study evaluating FP-
1039 in patients with metastatic or locally advanced-stage solid tumours has been 
completed122. In an unselected patient population, the best response was recorded to 
be stable disease (41.7%) and major adverse effects observed were diarrhoea 
(43.6%), fatigue (43.6%), and nausea (25.6%)122. No apparent relationship was 
reported between tumour response and FGF pathway aberrations in the 39 patients 
enrolled.  
[H1] Challenges and opportunities  
 
[H3] Challenges of patient selection 
 
Prospective selection of patients with specific FGFR aberrations is one of the major 
challenges in clinical trials. The overall infrequency of individual FGFR aberrations 
complicates identification of the best target population for each selective inhibitor. 
Further complicating early phase clinical trials have been basket trials, an approach 
that includes all patients with any FGFR aberration. As it has become clear that 
different FGFR aberrations have highly variable sensitivity to drugs, studies have 
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focused on individual aberrations123. Tumour biopsy material is often limited, and 
increasing evidence supports the potential to screen for FGFR aberration in plasma 
on circulating tumour DNA24. Non-invasive and inexpensive approaches like this 
could aid broader capture of genetic landscape of a tumour, and studies investigating 
detection of FGFR genetic aberrations in plasma are currently ongoing. 
 
Additional challenges have emerged in selecting patients with FGFR amplification, 
with ambiguity over the criteria for amplification and the importance of clonality in 
determining response. Early-phase trials of FGFR inhibitors selected patients on the 
basis of criteria used to define HER2 amplification (gene to centromere ratio >2), yet 
evidence suggests only tumours with higher FGFR copy number (gene to 
centromere ratio >4/5) are likely to respond to FGFR inhibition24. FGFR1 protein is 
frequently not overexpressed in cancers with lower levels of FGFR1 amplification124-
126, and mRNA levels of FGFR1 in those cases may be more reliable. Moreover, 
intra-tumour heterogeneity presents a major selection challenge. FGFR2 
amplification in gastric cancer is frequently sub-clonal109, with response observed 
only in cancers with clonal amplification24. The importance of clonality in response to 
mutations and fusions has yet to be explored. In general, oncogenic fusions are early 
truncal events in cancer, frequently occurring in genomically stable tumours, 
reinforcing the potential for therapeutic targeting of FGFR fusions. 
 
[H3] Variable addiction to FGFR amplification  
 
Increasing evidence suggests that only a fraction of cancers with FGFR aberrations 
are addicted to FGFR signalling. Differential activation of signal transduction 
pathways by different FGFRs and by distinct oncogenic events is likely critical in 
determining whether tumours depend on FGFR signalling to grow, which in turn may 
predict effectiveness of anti-FGFR therapy. FGF-mediated activation and regulation 
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of MAPK/ERK signalling is particularly important during organogenesis127,128; FGFRs 
have been shown to signal primarily through ERK1/2 during development, and FGF, 
FGFR, and ERK1/2 loss-of-function phenotypes are very similar129. In cancer, the 
MAPK/ERK signalling pathway is also most strongly activated by FGFR signalling 
across diverse aberrations, such as mutation or overexpression of the receptor 
molecules.. In many cellular contexts, this dominant signalling through the 
MAPK/ERK pathway is insufficient to drive addiction to FGFR signalling. Although 
FGFR signalling may contribute to oncogenesis and FGFR inhibition may result in 
reduced proliferation in cancer cell lines, this has not translated into single agent 
efficacy in the clinic. 
 
In vitro studies identified a moderate correlation between FGFR1 locus 8q12 
amplification and sensitivity to FGFR inhibitors in NSCLC10 and breast cancer130. Yet 
mouse models question whether FGFR1 amplification and overexpression induces 
oncogene addiction. Exogenous overexpression of FGFR1 in animal models does 
not result in malignant transformation, and induced dimerization of FGFR1 is 
required to trigger invasive properties in normal breast epithelial cell lines131 and 
transgenic mouse models of progressive mammary gland tumourigenesis132. In 
FGFR1-amplified cell lines, FGFR inhibition frequently results in inhibition of 
MAPK/ERK signalling, but without substantially affecting other signal transduction 
pathways such as PI3K/AKT signalling. Co-aberrant genes in FGFR1-amplified 
cancers may also result in reduced addiction to the FGFR pathway, including 
PIK3CA activating mutations and amplification of CCND132. Although FGFR1 may 
contribute to aspects of tumour progression, such as endocrine resistance in breast 
cancer (Box 2), FGFR1 is not a dominant oncogene.  
 
By contrast, FGFR2-amplified models seem to be highly addicted to FGFR signalling, 
and this is confirmed by an apoptotic response to FGFR inhibition, suggesting a 
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wider control of signal transduction and mTOR activity by FGFR2 signalling24. 
FGFR2 amplified at very high levels results in supra-physiological FGFR2 
expression, signalling and oncogene addiction, with a partial crosstalk between 
FGFR2 and other receptor tyrosine kinases, including ERBB3 (also known as HER3) 
and insulin growth factor receptor 1 (IGF1R)24.  
 
The mechanisms through which FGFR fusion proteins mediate addiction to FGFR 
signalling remain to be elucidated, and is likely to be cancer type-dependent. 
Overexpression of FGFR3 fusion proteins transformed 293T cells52 and Rat1A 
fibroblasts51, and enhanced cell proliferation compared with overexpression of wild-
type receptors52. Bladder cancer cell lines and xenograft models expressing fused 
FGFR3 proteins were sensitised to the FGFR inhibition51,55, although not by 
expression of FGFR3 containing hotspot mutations52,55.  
 
HCC harbouring FGF19 amplification may also represent a subset of cancers 
strongly addicted to the FGFR pathway. FGF19 amplification, and consequent ligand 
overexpression and FGFR4 activation, contribute to HCC development70. Pre-clinical 
data show that a blocking anti-FGFR4 monoclonal antibody (LD1) significantly 
reduced HCC xenograft growth133. A small-molecule inhibitor of FGFR4, BLU9931, 
with high selectivity against the other FGFR family members, suppressed tumour 
growth in HCC xenograft models with FGF19 amplification134. The pan-FGFR 
inhibitor JNJ-42756493, which inhibits FGFR4 at doses similar to those used to 
inhibit the other FGFR receptors, is currently being investigated in patients with 
advanced-stage HCC135 (Table 2). 
 
Collectively, these data have led to a growing understanding of the importance of 
identifying cancers strongly addicted to FGFR signalling. Although the potential of 
screening for mutations in FGFR2 and FGFR3 as biomarkers of response has been 
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demonstrated in xenograft models of NSCLC and head and neck squamous cell 
carcinoma (HNSCC), and in one patient136, many cancers with mutations in FGFR2 
and FGFR3 display limited FGFR-dependent signalling. Select cancers with high 
levels of FGF19 and FGFR2 amplification and FGFR fusions present putative 
biomarkers of FGFR addiction and confer sensitivity to targeted agents, unlike low-
level FGFR1 amplification.  
 
Combination therapeutic approaches may overcome the limitations of single agent 
FGFR inhibition in FGFR1-amplified cancers. Inhibitors of the PI3K-mTOR pathway 
are synergistic with FGFR inhibition, in part as mTOR activity is frequently only 
weakly inhibited by targeting FGFR, with synergy described both in vitro and in vivo 
in HNSCC cell lines16, endometrial cancer models137, gastric adenocarcinoma24 and 
HCC138. Despite these observations, combined individual toxic effects of these 
inhibitors will likely become a limiting factor in implementing this combination in the 
clinic.  
 
[H3] Toxicity limits pan-FGFR inhibition in the clinic  
On-target toxicity from pan-FGFR1-3 inhibition — including hyperphosphatemia , skin 
and eye dryness, keratopathy and asymptomatic retinal pigment detachment — limits 
dosing 139,140. Higher specificity with antibodies, or a next generation of selective 
inhibitors against a single FGFR, could minimise the appearance of adverse effects. 
Blockade of FGFs with the ligand binding trap FP-1039 reduced growth of FGFR1-
amplified lung cancer cell lines, xenografts121 and in a phase I study122, with no effect 
on serum calcium or phosphate levels. Similarly, a small-molecule ligand trap derived 
from long pentraxin 3 protein (NSC12) demonstrated potent anti-tumour action in 
FGFR-dependent xenograft models without systemic toxicity in the treated 
animals141.  
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[H3] Mechanisms of acquired resistance to FGFR inhibitors 
 
As with the majority of targeted treatments, a growing challenge of FGFR inhibition 
efficacy is development of drug resistance. In vitro studies have identified 
‘gatekeeper’ mutations in the FGFRs, and bypass activation of downstream 
signalling via alternate receptor tyrosine kinase, as frequent mechanisms of acquired 
or intrinsic resistance to targeted therapies (Figure 3).  
 
‘Gatekeeper’ mutations in the ATP binding cleft that induce resistance to FGFR 
inhibition have been identified pre-clinically. A ‘gatekeeper’ mutation FGFR3_V555M, 
along with comparable residues FGFR1_V561 and FGFR2_V564, induces 
resistance to multiple FGFR inhibitors in vitro142-144. Protein modelling studies 
suggest that these ‘gatekeeper’ mutations in the ATP cleft strengthen the 
hydrophobic spine of the kinase and may create a steric conflict to hinder drug-
binding efficiency143. The substitution of V561 for a ‘bulky’ Met amino acid resulted in 
complete disruption of FGFR1 binding to PD173074144. Although these studies 
demonstrate emergence of mutants resistant to FGFR inhibitors as mechanisms of 
acquired resistance pre-clinically, they are yet to be confirmed in samples of patient 
who have experienced clinical progression. In light of emergence of ‘gatekeeper’ 
mutations in FGFRs, irreversible covalent FGFR inhibitors that bind such FGFRs 
have been developed with the aim to overcome resistance to selective FGFR 
inhibitors145. 
 
Activation of alternative receptor tyrosine kinases, in particular the ERBB receptor 
family has been described as an escape mechanism in FGFR-resistant tumours. 
FGFR3-dependent bladder cancer cell lines developed rapid resistance to the FGFR 
inhibitor NVP-BGJ398 via switching to signalling through either ERBB2 (also known 
as HER2) or ERBB3 in a reversible manner, and correlated with an increased 
production of ERBB ligands, such as neuregulins 1, 2, 4 and betacellulin146. 
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Furthermore, dual inhibition of FGFR3 and EGFR activity in FGFR3-mutant bladder 
cancer cell lines resulted in increased cell death147. In FGFR1-amplified NSCLC cell 
lines resistant to FGFR therapy, PDGFRA and HER2 were reported to be co-
activated126. Use of novel approaches to allow detection of alternatively activated 
tyrosine kinase receptors or signalling pathways may augment selection of cancers 
for which FGFR inhibition is effective. 
 
[H1] Conclusion  
The great diversity of FGFR activating mechanisms has challenged the clinical 
translation of FGFR inhibitors, and the importance of considering individual 
aberrations is now clear from pre- and clinical evidence. Although some FGFR 
abnormalities are potential targets for monotherapy, such as high level and clonal 
amplification of FGFR2 or FGFR2/3 fusions, others do not seem to be biomarkers of 
response and need to be carefully evaluated in individual cancers against other 
potential oncogenic drivers. Taken together, preclinical and early clinical data 
demonstrate that targeting the FGFR signalling pathway can be a promising 
therapeutic strategy as monotherapy and in combination with other agents. 
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Box 1: Fibroblast growth factor receptor (FGFR) pathway signalling. 
 
The four fibroblast growth factor (FGF) receptors have extracellular, trans-membrane 
and cytoplasmic domains and can be detected in all adult tissues at varying levels148. 
The extracellular immunoglobulin-like loops bind FGFs, and in FGFR1-3, alternative 
splicing of the third loop, the IgIII domain, yields two isoforms (IIIb and IIIc) that vary 
in ligand-binding specificity, thus diversifying signalling patterns (Fig 2)2.  
FGF ligands are a family of 18 glycoproteins (FGFs 1-10 and 16-23) that influence 
organ development, wound repair and angiogenesis, via directly activating FGFRs. 
An additional four FGFs (FGF11-14) are not FGFR ligands and have unrelated 
intracellular functions2,149. The 15 canonical FGF ligands predominantly act in an 
autocrine and paracrine fashion binding to FGFRs in complex with heparan sulphate 
proteoglycans (HSPGs), which protect FGFs from degradation and stabilise FGF-
FGFR interaction150. The three endocrine FGFs (FGF19, 21 and 23) act as hormones 
and lack affinity for HSPG binding, which allows their diffusion from the site of 
production into the circulation151. They play a crucial part in bile acid, glucose and 
lipid metabolism, as well as control of vitamin D and phosphate levels, thereby 
maintaining whole-body homeostasis (reviewed in 152).  
FGF ligands induce dimerization and cross-phosphorylation of the kinase domains of 
cognate receptors, thus recruiting various downstream effector molecules. FGFR 
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substrate 2 (FRS2) is a key transducer of FGFR signalling2,153(Fig. 1). Upon 
dimerization of FGFRs, FRS2 binds to the juxtamembrane region of FGFRs and is 
consequently phosphorylated at several residues, which act as a docking site for son 
of sevenless (SOS) and growth factor receptor-bound 2 (GRB2). This complex in turn 
activates RAS-MAPK-ERK pathway.  
 
FGFR signalling can be diversified via recruitment of GRB2-associated binding 
protein 1 (GAB1) to FRS2 complex, thus activating PI3K/AKT signalling pathway. 
Another FGFR binding partner is phospholipase C γ (PLCγ), which binds at the C-
terminal tail upon autophosphorylation of FGFR, stimulating the release of 
intracellular calcium and consequent activation of the protein kinase C (PKC) family 
of proteins, thus resulting in cell migration, proliferation and cell differentiation154. In 
addition, FGFRs have the ability to activate JAK/STAT signalling pathway in a 
context-dependent manner43. Physiological negative regulation of FGFR signalling 
can be mediated by Cbl-regulated endocytosis and ubiquitination; MAPK 
phosphatases, which de-phosphorylate activated MAPK molecules; and SPROUTY 
and SPROUTY-related EVH1 domain-containing (SPRED) proteins, which bind to 
growth factor receptor-bound protein 2 (GRB2), thus attenuating downstream 
signaling155-157.  
Box 2. Resistance to therapy mediated by FGFR signalling.  
 
 
FGFR signalling may promote resistance to a variety of anti-cancer therapies. 
FGFR1 amplification has been implicated in driving endocrine resistance in breast 
cancer cell lines, in patient samples17,158, and associated with poor response to neo-
adjuvant chemotherapy in osteosarcoma159. There are ongoing studies evaluating a 
pan-FGFR inhibitor AZD4547 in combination with endocrine therapies fulvestrant160 
or letrozole and analstrozole161 in patients with oestrogen receptor (ER) positive 
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breast cancer. Combination short hairpin RNA (shRNA) screening identified FGFR1 
— but not other FGF receptors — as mediator of acquired resistance to the MEK 
inhibitor trametinib in KRAS-mutant lung cancer in vitro, and synergistic effects of 
trametinib with FGFR inhibitors were described in KRAS-mutant pancreatic 
xenografts and patient derived xenograft (PDX) models of lung cancer162. Elevated 
expression of FGFR2 and FGFR3 was described in NSCLC cell lines in response to 
gefinitib treatment163, suggesting the potential for combination therapy of FGFR and 
EGFR inhibitors in NSCLC. In addition, FGFR3 upregulation has been described to 
be an escape mechanism in vemurafenib-resistant BRAF-mutant melanoma164 and 
gastric cancer cell lines resistant to MET-targeted therapy165. 
Cancer evolution may lead to selection of FGFR activating mutations in some 
tumours. Hotspot mutations in FGFR1166 and FGFR2167 were shown to be acquired 
during chemotherapy and endocrine therapy in breast cancer, and a novel driver 
FGFR3 mutation was described in PDX models of EGFR tyrosine kinase inhibitor-
resistant lung cancer 168. Similarly, FGF ligands may also mediate resistance to 
targeted therapies. Activation of FGF2-FGFR1 autocrine loop has been described to 
be a mechanism of acquired resistance in gefitinib-resistant169,170, as well as afatinib-
resistant NSCLC cell lines171, in which selective FGFR inhibitors re-sensitised cells to 
EGFR therapies. Patients who progressed on anti-VEGF therapy exhibited elevated 
FGF2 levels in plasma93,possibly due to overlapping roles of FGF2, VEGF and PDGF 
in angiogenesis. Additionally, in vivo studies proposed that targeting FGFR could 
restore sensitivity to anti-VEGF therapies94. In a cervical cancer xenograft model, 
treatment with a PDGFR inhibitor imatinib resulted in upregulation of FGF2 and 
FGF7 by the stroma, thus promoting tumour proliferation and angiogenesis172. More 
recently, higher levels of FGF2 were described in biopsy samples from patients with 
imatinib-resistant gastrointestinal stromal tumours (GIST) compared with specimens 
from patients who had not been treated with imatinib 173. Therefore, these findings 
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strongly suggest that FGFR inhibition may revert acquired resistance to anti-cancer 
therapies. 
 
 
 
Figure 1. Mechanisms of oncogenic FGFR signalling.  
 
FGFR signalling contributes to oncogenesis in several ligand-dependent and –
independent mechanisms. 1. FGFR gene amplification often translates into protein 
overexpression, leading to elevated receptor accumulation and activation of the 
downstream signalling pathways. 2. Activating mutations often result in increased 
dimerization of the receptors in the absence of ligand, or constitutive activation of the 
kinase domain. 3. As a result of chromosomal translocations, parts of FGF receptors 
may become fused with genes encoding other proteins at either C- or N-termini, 
thereby either increasing dimerization of the receptors (purple fusion), or falling under 
the promoter regions of a different protein (blue fusion), resulting in receptor hyper-
activation in a ligand-independent manner. 4. FGFRs can be over-stimulated by their 
ligands in autocrine fashion, in which FGFs are produced by the tumour cells (light 
blue); or via paracrine signalling, where FGFs are secreted by the stromal 
compartment (dark blue). In response to a stimulus, or due to gene amplification, the 
third IgIII loop can also be alternatively spliced from IIIb to IIIc isoform, which alters 
the receptors’ ligand specificity and affinity, resulting in altered autocrine signalling. 5. 
FGFs secreted by the tumour cells, or tumour-associated stromal cells, may also 
contribute to angiogenesis or 6, epithelial-mesenchymal transition (EMT), which are 
implicated in tumour progression. 7. Deregulation of FGFR binding partners FRS2 
and PLCγ due to their gene amplification or protein overexpression can lead to 
hyper-activation of the FGFR downstream signalling pathways. 
 
Figure 2. Structure of FGFR and frequency of the receptors’ somatic mutations 
with their relative locations. 
 
FGF receptors consist of an extracellular domain encompassing three Ig-like 
domains (IgI-III), followed by a transmembrane domain and two tyrosine kinase sub-
domains, TK I and TK II. An acidic box, which is a stretch of acidic amino acids 
responsible to FGFR interaction with partners other than FGFs, is located between 
IgI and IgII, and a heparan sulfate proteoglycan-binding domain, which helps 
stabilise FGF-FGFR interaction, is found on IgII. IgIII can be alternatively spliced to 
yield IIIb or IIIc isoforms.  
The second part of the figure shows the frequency of FGFR somatic mutations 
reported in patients with cancer and their relative location on the proteins. Residue 
locations correspond to various regions on the receptors, using FGFR1 molecule as 
a reference. Mutations in FGFR1 and FGFR4 are not frequently reported, but 
mutations in FGFR2 and FGFR3 are common and occur predominantly in the ligand-
binding and transmembrane domains of the receptors, with fewer mutations reported 
in the kinase domains. Graphs were created using raw data extracted from COSMIC, 
GRCh37174, using the following filters: Tumour source= tumour sample; mutation 
type= insertions/deletions (both frameshift and in-frame), missense; mutation type= 
pathogenic, as determined by the Functional Analysis through Hidden Markov 
Models algorithm, where scores are ≥ 0.7175.  
 37 
 
Figure 3. Mechanisms of resistance to FGFR inhibitors. 
 
Mechanisms of resistance to targeted anti-FGFR therapies are beginning to emerge, 
although predominantly from in vitro functional studies. (a.) Prolonged treatment of 
cell lines with selective FGFR inhibitors can result in emergence of point mutations in 
FGFR kinase domains, contributing to the conformational changes preventing 
adequate drug binding in select models. Alternatively, other RTKs, such as IGF1R or 
ERBB family members, may become upregulated in response to FGFR therapy, 
thereby serving as a bypass mechanism for activation of cell survival and 
proliferative pathways. (b.) PI3K signalling pathway is frequently implicated in 
mediating resistance to FGFR inhibitors, by either directly affecting cell proliferation, 
or via activation of mTOR and consequent alteration in cell metabolism and anti-
apoptotic signals. KRAS activating mutations or amplification can in turn stimulate 
MAPK/ERK signalling pathway when FGFR signalling is unavailable.  
 
Table 1. FGFR fusion partners51,52,56. 
 
Abbreviations: CDS-5UTR, the 5’ untranslated region of a protein coding sequence; 
In-frame, a fusion transcript without a frame shift, resulting in transcription of both 
genes; Out-of-frame, a fusion transcript that causes a frame shift in one of the genes. 
InterChr, inter-chromosomal fusion.  
 
Cancer Type 5' gene 3' gene Cases Reported Frame Fusion Type
Bladder'Cancer FGFR3 TACC3 3/ 121 In,frame Short
FGFR1 ADAM18 1/ 1019 Out,of,frame Middle
RHOT1 FGFR1 1/ 1019 CDS,5UTR InterChr
WHSC1L1 FGFR1 2/ 1019 In,frame Short
FGFR2 CCDC6 1/ 1019 In,frame Long
Glioblastoma FGFR3 TACC3 6/ 158 In,frame Short
FGFR3 TACC3 2/ 300 In,frame Short
FGFR3 TPRG1 1/ 300 Out,of,frame InterChr
FGFR2 AHCYL1 7/ 66 In,frame InterChr
FGFR2 BICC1 2/ 66 In,frame InterChr
FGFR3 ELAVL3 1/ 266 In,frame InterChr
FGFR3 TACC3 1/ 266 In,frame Short
Lung'Adenocrcinoma FGFR1 SLC20A2 1/ 487 CDS,5UTR Middle
BAG4 FGFR1 1/ 220 In,frame Short
FGFR2 KIAA1967 1/ 220 In,frame InterChr
KIAA1967 FGFR2 1/ 220 5UTR,CDS InterChr
FGFR3 TACC3 5/ 220 In,frame Short
Ovarian'Cancer FGFR2 USP10 1/ 400 In,frame InterChr
SLC45A3 FGFR2 1/ 84 CDS,5UTR InterChr
FGFR3 AES 1/ 178 In,frame InterChr
FGFR2 OFD1 1/ 494 In,frame InterChr
VCL FGFR2 1/ 494 In,frame Long
Breast'cancer
Head'and'Neck'Squamous'Cell'Carcinoma
Intrahepatic'Cholangiocarcinoma
Low,grade'Glioma
Lung'Squamous'Cell'Carcinoma
Prostate'Adenocarcinoma
Thyroid'Carcinoma
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Table 2. Summary of FGFR inhibitors currently investigated in clinical trials: 
IC50 and their progress.  
* Values listed were obtained in cell-free assays121,139,140,176-182, except #median 
reported IC50, obtained using cell lines  
 
Company Target IC50 Drug Clinical trial ID Phase I Phase II Phase III
FLT3 1 nM
c-Kit 2 nM
FGFR1 8 nM
VEGFR3/FLT4 8 nM NCT01732107 FGFR3-mutated or -overexpressed urothelial cancer
FGFR3 9 nM
VEGFR1/FLT1 10 nM
Abl <1 nM
PDGFRa 1.1 nM
VEGFR2 1.5 nM
FGFR1 2.2 nM
c-Src 5.4 nM
VEGFR1 7 nM NCT01283945 FGFR1-amplified advanced solid tumours
VEGFR3 10 nM NCT02202746 FGFR genetically-aberrant metastatic breast cancer
FGFR1 18 nM NCT02053636 FGFR1/11q-amplified ER+ metastatic breast cancer
VEGFR2 25 nM
FGFR2 83 nM
FGFR1 <1 nM NCT02664935 FGFR genetically-aberrant non-small cell lung cancer
FGFR3 1.8 nM NCT02117167 FGFR genetically-aberrant metastatic non-small cell lung cancer
FGFR2 2.5 nM
VEGFR2 24 nM
FGFR1 <1 nM NCT01004224
FGFR1-3 genetically aberrant solid 
tumours; FGFR1-amplified squamous 
lung cancer; FGFR3-mutated or fused 
bladder cancer
FGFR3 1 nM NCT01697605 FGFR genetically-aberrant advanced solid tumours in Asian population
FGFR2 1.4 nM NCT01928459 FGFR genetically-aberrant advanced solid tumours with PIK3CA mutations
FGFR3 (K650E) 4.9 nM NCT01975701
Glioma subtypes with FGFR1-TACC1, 
FGFR3-TACC3 fusion and/or activating 
mutation in FGFR1-3.
FGFR4 60 nM NCT02160041 FGFR genetically-aberrant solid and/or hematologic cancers
NCT02150967 FGFR genetically-aberrant advanced or metastatic cholangiocarcinoma 
FGFR1 <1 nM NCT02421185 FGF19-amplified advanced hepatocellular carcinoma
FGFR2 <1 nM NCT02365597 FGFR genetically-aberrant advanced/metastatic urothelial cancer
FGFR4 <1 nM
FGFR3 1.05 nM
FGFR3 (G697C) 1.9 nM
FGFR1 2.8 nM
FGFR2 2.6 nM
FGFR3 6.4 nM
FGFR4 6 nM
VEGFR2 7nM
FGFR1 3.9 nM
FGFR2 1.3 nM
FGFR3 1.6 nM
FGFR4 8.3 nM
FGFR2 7.6 nM
FGFR1 9.3 nM
FGFR3 22 nM
GSK FGF2 0.023 µg/ml FP-1039 NCT01868022
FGFR genetically-aberrant solid 
malignancies in combination with 
paclitaxel and carboplatin/docetaxel
Five Prime 
Therapeutics FGFR2_IIb FPA114 NCT02318329 Advanced solid tumours
Genentech, 
Inc. FGFR3 MFGR1877S NCT01363024 Advanced solid tumours
Debio-1347
NCT01223027 Metastatic renal cell cancer
NCT01719549 FGFR2-amplified gastric cancer
NCT02272998 FGFR genetically-aberrant advanced cancers
NCT02265341
LY2874455 
TAS120
BGJ398
JNJ-
42756493
Lucitanib
AZD4547
Dovitinib
Asian participants with non-small-cell lung 
cancer, gastric cancer, urothelial cancer, 
esophageal cancer and 
cholangiocarcinoma.
NCT01212107 Advanced cancer
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